<DOC>
	<DOCNO>NCT00350519</DOCNO>
	<brief_summary>The primary purpose study compare effect perioperative ( time period describe duration participant surgical procedure ) administration PROCRIT Standard Care ( SOC ) proportion participant receive pRBC ( pack red blood cell ) transfusion ( day surgery day hospital discharge ) participant undergo elective major abdominal and/or pelvic surgery . Standard Care define treatment participant accord hospital institution 's policy , participant receive PROCRIT ( Epoetin alfa ) erythropoiesis-stimulating agent ( ESAs ) ( agent stimulate production red blood cell bone marrow ) .</brief_summary>
	<brief_title>The Safety Effectiveness PROCRIT ( Epoetin Alfa ) Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , parallel-arm ( group participant treat time ) , open-label ( people know identity intervention ) , multicenter study . The study consist screen phase 21 day , treatment phase 15 day , follow-up phase 28 day . Approximately 110 participant undergo elective major abdominal and/or pelvic surgery enrol . During Treatment Phase , eligible participant randomly assign ( participant assign treatment group base chance ) 1:1 ratio either PROCRIT ( Epoetin alfa ) Standard Care ( SOC ) group receive erythropoiesis-stimulating agent ( ESAs ) . Participants undergo surgery Treatment Phase . After surgery , participant stay study 4 day ( hospital discharge ) follow additional 28 day ( Follow-up Phase ) . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The duration study participant approximately 64 day .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Scheduled undergo elective major abdominal and/or pelvic surgery anticipate significant perioperative ( ( time period describe duration participant surgical procedure ) blood loss ( eg , great 500 cc increase risk blood transfusion ) Hemoglobin great 10 g/dL less equal 13 g/dL screening ( Day 13 [ 13 day prior surgery ] Day 11 ) baseline ( Day 10 ) Patients reproductive potential partner must practice effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , partner sterilization ) entry throughout study Female patient reproductive potential must negative urine pregnancy test within 7 day first dose PROCRIT Adequate renal ( kidney ) adequate hepatic ( liver ) function assess within 21day screen period No severe Congestive Heart Failure ( New York Heart Association Class IV ) No know severe stable unstable coronary artery disease , unstable angina No history deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) within 12 month study entry ( prior superficial thrombophlebitis exclusion criterion ) No history cerebrovascular accident ( CVA ) , transient ischemic attack ( TIA ) , Acute coronary syndrome ( unstable Angina , myocardial Infarction ) , arterial thrombosis within 6 month study entry Not anticipate donate perioperative autologous blood receive transfusion within 21 day prior baseline great 6 transfusion perioperatively No prior treatment PROCRIT erythropoiesisstimulating agent ( ESAs ) within previous month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hemostasis , Surgical</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Surgery</keyword>
	<keyword>Abdomen</keyword>
	<keyword>Pelvis</keyword>
	<keyword>PROCRIT</keyword>
	<keyword>pRBC</keyword>
	<keyword>Blood transfusion</keyword>
	<keyword>Packed red blood cell transfusion</keyword>
</DOC>